CClinicalTrials.gg
Status unknownNCT03966222Updated Sep 22, 2021

Comparison of Saphenous Vein Harvesting by Endoscopic Versus Open Conventional Methods

An interventional study of Endoscopic vein harvest and Open vein harvest in Coronary Artery Disease, sponsored by Sheba Medical Center. Status unknown at 1 site in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-22.

Sponsored by Sheba Medical Center · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2021), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The aim of this study is to investigate the histological and immunohistochemical findings of the saphenous vein graft, to rule out endothelial damage as a direct result of manipulation or instrumentation by endoscopic and open conventional harvesting methods. Furthermore, to investigate if there are any differences in the surgical site infection, cardiac event and functional status between the two harvest strategies at 1-year of follow-up.

Read the detailed description

BACKGROUND Ischemic heart disease is the leading cause of death globally that accounts for about 7.4 million mortalities worldwide annually as published by the World Health Organization. Coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) are the options for revascularization in patients suffering from coronary artery disease (CAD). The choice of the most appropriate modality is affected by the clinical presentation, comorbidities, anatomical complexity of the CAD, and baseline characteristics of the patient. Although advances in PCI with drug-eluting stents have provide good outcomes, CABG remains an important revascularization strategy in the treatment of CAD.

The initial experience of using saphenous vein as coronary bypass conduits was first published from the Cleveland clinic in 1967. Minimally invasive endoscopic vein harvest (EVH) was first reported in 1996 as an alternative to open vein harvest (OVH). An endoscope is introduced adjacent to the vein, allowing its dissection under direct vision via a small incision. Over the last decade, EVH has become the preferred technique for conduit harvest in many cardiothoracic centers owing to the overall reduction in complications compared with OVH and the obvious cosmetic advantage. However, concerns persist regarding the risk of microscopic damage incurred during EVH, and the consequences of this for long-term graft patency.

OBJECTIVES The aim of this study is to investigate the histological and immunohistochemical findings of the saphenous vein graft, to rule out endothelial damage as a direct result of manipulation or instrumentation by endoscopic and open conventional harvesting methods. Furthermore, to investigate if there are any differences in the surgical site infection, cardiac event and functional status between the two harvest strategies at 1-year of follow-up.

METHODS This is a prospective, single-center randomized controlled trial conducted in the department of cardiac surgery at the Sheba Medical Center. It will include a sample size of 50 patients (randomization ratio 1:1), who are planned to undergo an elective isolated CABG surgery, and a vein graft is necessary for the revascularization.

02

Conditions studied

  • Coronary Artery Disease

Keywords

  • Vein graft
03

In context

Coronary Artery Disease

5,598 studies on the registry are indexed under Coronary Artery Disease; 957 are open to participants now.

This study's planned enrollment of 50 is below the median of 124 across 3,436 interventional studies indexed under Coronary Artery Disease.

Browse Coronary Artery Disease studies →

Lead sponsor

Sheba Medical Center is the lead sponsor of 660 studies on the registry; 63 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Male or female patients over the age of 18;
  • Patients with ischemic heart disease who are planned to undergo CABG surgery;
  • A vein graft in necessary for the revascularization;
  • There is no indication for one specific method for vein harvesting;
  • Informed consent obtained.

Exclusion criteria

Exclusion Criteria:

  • Patients who undergo a non-elective surgery
  • Concomitant procedures during the CABG surgery;
  • Any known infection in the past 6 months;
  • Evidence of vein thrombosis in an ultrasound study prior to surgery;
  • Morbid obesity patients;
  • Patients with peripheral vascular disease;
  • Patients who would gain from one technique more than the other by any reason (according to the surgeon or investigator opinion);
  • Severe primary mitral and aortic valve stenosis or regurgitation;
  • Patients who have undergone a previous cardiac surgery from any kind;
  • Patients who underwent any surgery in the lower extremities in the past (i.e. orthopedic, vascular, etc.);
  • Any serious disease likely to interfere with the conduct of the study;
  • Participation in other clinical trial;
  • Patients geographically not stable or unavailable for follow-up.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    Open vein harvest

    For the standard open conventional technique, the saphenous vein will be exposed by a longitudinal leg incision starting from the medial malleolus and ending at the upper medial thigh at the sapheno-femoral junction. The saphenous vein will be dissected free from its perivascular fat pedicle and visible side branches will be ligated and divided.

    Other: Open vein harvest

  • Experimental
    Endoscopic vein harvest

    We will use the Terumo VirtuoSaph® Plus Endoscopic Vessel Harvesting System for all endoscopic vein extractions, which is an open carbon dioxide (CO2) system. Approximately 6 l/min of CO2 will be continuously insufflated in the subcutaneous tunnel.

    Device: Endoscopic vein harvest

Interventions

  • DeviceEndoscopic vein harvest

    An endoscope is introduced adjacent to the vein, allowing its dissection under direct vision via a small incision.

  • OtherOpen vein harvest

    Open vein harvest

06

What researchers measure

Primary outcomes

  1. Microscopic vein damage by histology examination

    The amount of preserved endothelium and endothelial stretching seen in the histology examination in the two different vein harvesting strategies.

    Time frame: Immediate

Secondary outcomes

  1. Rehospitalization, myocardial infarction and all-cause mortality

    Composite end point of rehospitalization, myocardial infarction and all-cause mortality up to 1-year.

    Time frame: 12 months

  2. New-York Heart Association (NYHA) functional class

    New-York Heart Association (NYHA) functional class at 1-year

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • Sheba Medical Center
    Ramat Gan, Israel
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03966222
Lead sponsor
Sheba Medical Center
Responsible party
Dr. Eilon Ram (Principal Investigator, Sheba Medical Center) — Principal investigator
First posted
May 29, 2019
Start date
Jan 1, 2020
Primary completion
Jul 1, 2022 (estimated)
Completion
Jul 1, 2022 (estimated)
Last update
Sep 22, 2021

Study contacts

Eilon Ram, M.D.
Contact
eilon.ram@sheba.health.gov.il
3-5302710 ext. 972
Leonid Sternik, M.D.
study director · Sheba Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion